Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SZ09628
- Development stage
- Preclinical
- Lead developer
- Sarfez Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SZ09628 is a preclinical-stage small molecule new chemical entity (NCE) under development by Sarfez Pharmaceuticals. The drug is being investigated for the treatment of labile hypertension and anxiety, conditions characterized by unpredictable fluctuations in blood pressure often associated with psychological stress. As an NCE, it represents a novel chemical structure within the company's cardiovascular and central nervous system pipeline. While the specific molecular target has not been publicly disclosed, the program aims to address the physiological and psychological components of blood pressure variability.
Beyond the preview
Go deeper on SZ09628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SZ09628.